Revenue Increases 26.7 Percent, CHEK Proves Strategy Promises Through First Semester 2025 Financial Performance

JAKARTA - It has only been 2 weeks since it officially took the floor on the Indonesia Stock Exchange, PT Diastika Biotegundo Tbk (CHEK) has displayed its commitment to transparency and accountability. This diagnostic medical device company released a first semester 2025 financial report that reflects not only growth, but also the realization of the promised strategy.

In the report, CHEK recorded an increase in revenue of 26.7 percent to Rp78.3 billion, more than that, the company earned a net profit of Rp5.26 billion. Each row of reports reflects a clear direction, grows healthyly, maintains margins, and builds sustainable profitability.

"This first semester 2025 financial report strengthens our foundation to continue to grow as an open company. This proves the readiness of Biotegundo Diastika to present sustainable added value for shareholders and stakeholders," said President Director of PT Diastika Biotegundo Tbk, FX Yoshua R, Thursday, July 31.

The recently implemented IPO is a strategic step to strengthen working capital, expand national distribution, and develop superior diagnostic product lines. Along with strengthening cost efficiency and improving sales services which begin to create recurring income.

"With this transparency, we want to build long-term trust and open the door for more investors to be part of the transformation of the national medical device industry," said FX Yoshua R.

Long-Term Transparency Commitment, CHEK sent an important message to investors, that growth was not only planned, but was actually implemented. This achievement is a strong starting signal that our business fundamentals continue to strengthen after the IPO. We are committed to providing sustainable results for all shareholders, said FX Yoshua R, President Director of PT Diastika Biotegundo Tbk.

The company will continue to strengthen its position as a reliable provider of diagnostic medical devices, focusing on product innovation and increasing distribution reach to various regions in Indonesia. The Company is committed to continuing to encourage innovation in the diagnostic medical device sector and expanding access to rapid, accurate, and affordable diagnostic services throughout Indonesia.

"Transparency for us is not a matter of obligation, but a strategy with the expansion of Domestic Diagnostic Medical Devices products as a strengthening of the manufacturing capacity of domestic medical devices to strengthen the national health equipment ecosystem and provide more affordable diagnostic solutions and easily accessible to the public through government programs (tenders) which are currently still in process, we can grow together with investors and the effectiveness of our strategy in optimizing income and operational efficiency, amid growing demand for diagnostic solutions in Indonesia," said FX Yoshua R.

In the diagnostic medical device sector, efficiency and distribution speed are key. Improved financial performance can strengthen the narrative that CHEK is market-driven and scalable by proving positive growth after the IPO, with a clear and measurable business direction. Management has proven to be able to maintain efficiency and expansion together in less than 6 months after the IPO.